

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

Voluntary Announcement Protected Product of Traditional Chinese Medicine

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the updates on the development of the business of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 28 April 2025, the National Medical Products Administration released the “Announcement on Protected Product of Traditional Chinese Medicine (No.25) (No. 45 of 2025)” setting out that our product, namely Kidney Repair and Edema Alleviation Granules (益腎化濕顆粒) (the “**Product**”), has been approved as a Class 2 Protected Product of Traditional Chinese Medicine pursuant to the Regulations on the Protected Product of Traditional Chinese Medicine (《中藥品種保護條例》) and Guangzhou Consun Pharmaceutical Company Limited (廣州康臣藥業有限公司) (“**Guangzhou Consun**”), a wholly-owned subsidiary of the Company, has been granted with the Certificate of Protected Product of Traditional Chinese Medicine (the “**Certificate**”), Certificate No: (2025) Guo Yao Zhong Bao Zheng Zi No. 009.

The Product is entitled for a state protection period of 7 years, which can be renewed upon further application. During the protection period, other enterprises are prohibited from imitating the Product. As at date of this announcement, Guangzhou Consun is the sole holder of the Product and the Certificate.

The Board believes that such recognition is a state support to the Product and will be beneficial to the Group’s long-term development in the future.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Consun Pharmaceutical Group Limited
AN Meng
Chairman

Hong Kong, 30 April 2025

As at the date of this announcement, the Board comprises Mr. An Meng, Professor Zhu Quan and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.